Sanctuary Advisors LLC Sells 1,800 Shares of Organon & Co. (NYSE:OGN)

Sanctuary Advisors LLC lessened its stake in Organon & Co. (NYSE:OGN) by 0.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 242,055 shares of the company’s stock after selling 1,800 shares during the period. Sanctuary Advisors LLC’s holdings in Organon & Co. were worth $3,866,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in the stock. Sippican Capital Advisors grew its position in Organon & Co. by 4.3% in the 3rd quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock worth $291,000 after purchasing an additional 627 shares during the period. Commerce Bank boosted its stake in shares of Organon & Co. by 5.5% during the 3rd quarter. Commerce Bank now owns 12,168 shares of the company’s stock worth $233,000 after acquiring an additional 637 shares during the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Organon & Co. by 32.4% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after acquiring an additional 672 shares during the last quarter. Graypoint LLC boosted its stake in shares of Organon & Co. by 6.2% during the 3rd quarter. Graypoint LLC now owns 14,555 shares of the company’s stock worth $278,000 after acquiring an additional 853 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB boosted its stake in shares of Organon & Co. by 12.9% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 10,910 shares of the company’s stock worth $163,000 after acquiring an additional 1,248 shares during the last quarter. Institutional investors own 77.43% of the company’s stock.

Organon & Co. Stock Down 1.4 %

OGN opened at $15.47 on Friday. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. Organon & Co. has a fifty-two week low of $13.87 and a fifty-two week high of $23.10. The firm’s fifty day moving average is $15.36 and its 200 day moving average is $17.28. The stock has a market cap of $3.98 billion, a price-to-earnings ratio of 4.64, a price-to-earnings-growth ratio of 0.85 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The firm had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.57 billion. On average, sell-side analysts forecast that Organon & Co. will post 3.78 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.24%. The ex-dividend date of this dividend is Monday, February 24th. Organon & Co.’s dividend payout ratio (DPR) is 33.63%.

Wall Street Analysts Forecast Growth

OGN has been the topic of several analyst reports. Barclays dropped their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Morgan Stanley dropped their price target on shares of Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research note on Friday, February 14th. Finally, TD Cowen upgraded shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $20.80.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.